Zealand inks deal with OTR Therapeutics as it spells out broader metabolic disease ambitionsnews2025-12-11T12:12:44+00:00December 11th, 2025|Endpoints News|
Formation Bio signs deal for TYK2 drug from China’s Lynknews2025-12-10T12:00:15+00:00December 10th, 2025|Endpoints News|
Novartis to partner with AI-focused Relation on atopic diseasesnews2025-12-09T16:19:37+00:00December 9th, 2025|Endpoints News|
Eli Lilly will be ‘aggressive’ in spending GLP-1 money, top dealmaker Van Naarden saysnews2025-12-09T12:30:22+00:00December 9th, 2025|Endpoints News|
Pfizer to pay $150M upfront for small molecule GLP-1 from Fosun subsidiarynews2025-12-09T12:01:17+00:00December 9th, 2025|Endpoints News|
GSK walks away from remaining Ideaya programsnews2025-12-08T18:55:55+00:00December 8th, 2025|Endpoints News|
Merck outbid three competitors in Cidara acquisition — new filingnews2025-12-08T14:41:45+00:00December 8th, 2025|Endpoints News|
Mirum to pay $620M for Bluejay and its hepatitis D antibodynews2025-12-08T13:00:20+00:00December 8th, 2025|Endpoints News|
Crescent forms PD-1xVEGF, ADC pact with Kelun, raises $185Mnews2025-12-04T14:04:35+00:00December 4th, 2025|Endpoints News|
ARCH, Parker Institute build next big oncology bet with suite of programs and startup acquisitionnews2025-12-02T16:34:33+00:00December 2nd, 2025|Endpoints News|
